Docket No.: C17858/120103

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

STEVEN J. RYCHNOVSKY

Serial No.: 09/871,441

Filed: May 31, 2001

For: METHOD FOR IMPROVING TREATMENT SELECTIVITY AND EFFICACY USING INTRAVASCULAR PHOTODYNAMIC THERAPY

Examiner: R. Henley, III

Art Unit: 1614

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

In the Specification

A. Replace the paragraph at page 4, line 20 through page 5, line 8 with the following paragraph:

Other studies have investigated the inhibition of neointima formation in natural vein grafts in which, prior to implantation, the graft receives a PDT treatment using 675 nm light (G. M. LaMuraglia, et al., Photodynamic Therapy of Vein Grafts: Suppression of Intimal Hyperplasia of the Vein Graft but not the Anastomosis, J Vascular Surg, 21, 1995). Still further studies have investigated the reduction or stabilization of plaques in diseased artery animal models using a photosensitizer delivered systemically and excited with either external or intravascular light with a wavelength near 730 nm. These studies led to the application of PDT in human clinical trials using Lutetium texaphyrin (LuTex) in combination with a laser source having a wavelength near 730 nm (S. G. Rockson, et al., Photoangioplasty: An Emerging Clinical Cardiovascular Role for Photodynamic Therapy, Circulation, 102, 591-96, 2000). These human clinical trials have two primary efficacy endpoints: inhibition of restenosis